Evidence map›Paper›PMID 36909862›Full record

ArticleJournal of orthopaedic translation2023

Pharmacological network analysis of the functions and mechanism of kaempferol from Du Zhong in intervertebral disc degeneration (IDD).

Xiaobin Wang, Yanlin Tan, Fusheng Liu, Jingyu Wang, Fubin Liu, Qianshi Zhang, Jing Li

Abstract read
In one paragraph

Article in Journal of orthopaedic translation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Network-Based Identification ofCurrent pharmaceutical design · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. The JNK signaling pathway in intervertebral disc degeneration.Frontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaobin WangDepartment of Spine Surgery, Spinal Deformity Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Yanlin TanPET/CT Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Fusheng LiuDepartment of Spine Surgery, Spinal Deformity Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Jingyu WangDepartment of Spine Surgery, Spinal Deformity Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Fubin LiuDepartment of Spine Surgery, Spinal Deformity Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Qianshi ZhangDepartment of Spine Surgery, Spinal Deformity Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Jing LiDepartment of Spine Surgery, Spinal Deformity Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Senescence and apoptosis of the nucleus pulposus cells (NPCs) are essential components of the intervertebral disc degeneration (IDD) process. Senescence and anti-apoptosis treatments could be effective ways to delay or even stop disc degeneration. IDD has been treated with Methods: Traditional Chinese Medicine Systems Pharmacology (TCMSP) database was used to select the main active ingredients of DZ with the threshold of oral bioavailability (OB) ​≥ ​30% and drug-likeness (DL) ​≥ ​0.2. GSE34095 contained expression profile of degenerative intervertebral disc tissues and non-degenerative intervertebral disc tissues were downloaded for different expression genes analysis. The disease targets genes of IDD were retrieved from GeneCards. The online tool Metascape was used for functional enrichment annotation analysis. The specific effects of the ingredient on IL-1β treated NPC cell proliferation, cell senescence, reactive oxygen species (ROS) accumulation and cell apoptosis were determined by CCK-8, SA-β-gal staining, flowcytometry and western blot assays. Results: A total of 8 active compounds of DZ were found to meet the threshold of OB ​≥ ​30% and DL ​≥ ​0.2 with 4151 drug targets. After the intersection of 879 IDD disease targets obtained from GeneCards and 230 DEGs obtained from the IDD-related GSE dataset, a total of 13 hub genes overlapped. According to functional enrichment annotation analysis by Metascape, these genes showed to be dramatically enriched in AGE-RAGE signaling, proteoglycans in cancer, wound healing, transmembrane receptor protein tyrosine kinase signaling, MAPK cascades, ERK1/2 cascades, PI3K/Akt signaling pathway, skeletal system, etc. Disease association analysis by DisGeNET indicated that these genes were significantly associated with IDD, intervertebral disc disease, skeletal dysplasia, and other diseases. Active ingredients-targets-signaling pathway networks were constructed by Cytoscape, and kaempferol was identified as the hub active compound of DZ. In the IL-1β-induced IDD Conclusion: Kaempferol has been regarded as the major active compound of DZ, protecting NPCs from IL-1β-induced damages through promoting cell viability, inhibiting cell senescence and apoptosis, increasing ECM production, and decreasing ECM degradation. MAPK signaling pathway may be involved. The translational poteintial of this article: This study provides

Indexed as

DZ)Eucommia ulmoides Oliver (du zhongIntervertebral disc degeneration (IDD)KaempferolNetwork pharmacologyNucleus pulposus cell (NPC)

Identifiers

PMID36909862
PMCPMC9999173

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.